Liminatus Pharma (LIMN) Cash from Operations (2024 - 2026)
Liminatus Pharma (LIMN) posted Cash from Operations of 2015289.0 for Q1 2026, down 420.95% sequentially from 386847.0 in Q4 2025, and down 1164.35% YoY from 189344.17 in Q1 2025.
Liminatus Pharma (LIMN) Cash from Operations (2024 - 2026) Analysis & Trends
Liminatus Pharma has reported Cash from Operations for 3 years, with the latest figure at 2015289.0 in Q1 2026.
- Quarterly Cash from Operations fell 1164.35% year-over-year to 2015289.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 11819214.0 (down 633.9% YoY) and the FY2025 annual result came in at 9963318.0, down 586.62% from the prior year.
- Cash from Operations fell to 2015289.0 in Q1 2026 per LIMN's latest filing, from 386847.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 140660.0 in Q4 2024 and troughed at 8816466.0 in Q2 2025.
- A 3-year average of 1678709.12 and a median of 493729.5 in 2025 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2025 and 2026: Cash from Operations plunged 175.02% in 2025, then slumped 1164.35% in 2026.
- Over 3 years, Cash from Operations stood at 140660.0 in 2024, then slumped by 175.02% to 386847.0 in 2025, then sank by 420.95% to 2015289.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 2015289.0, 386847.0, and 600612.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Liminatus Pharma | 256.03 Mn | 256.03 Mn | - | -969,999.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.02 Mn |
| Mar 31, 2026 | -2.02 Mn |
| Dec 31, 2025 | -386,847.00 |
| Dec 31, 2025 | -386,847.00 |
| Sep 30, 2025 | -600,612.00 |
| Sep 30, 2025 | -600,612.00 |
| Jun 30, 2025 | -8.82 Mn |
| Jun 30, 2025 | -8.82 Mn |
| Mar 31, 2025 | -159,393.00 |
| Mar 31, 2025 | -159,393.00 |
| Dec 31, 2024 | -140,660.00 |
| Dec 31, 2024 | -140,660.00 |
| Sep 30, 2024 | -206,119.00 |
| Sep 30, 2024 | -206,119.00 |
| Jun 30, 2024 | -1.10 Mn |
| Jun 30, 2024 | -1.10 Mn |